The present invention relates to methods and compositions for treating B-CLL in particular of patients with poor prognosis B-CLL, such as the sub-type of B-CLL which is characterized by the presence of an expression product. Accordingly it is an object of the invention to destroy or eliminate the transcription of said expression product by i.e. providing a medicament capable of decreasing or inhibiting the formation of said expression product. Furthermore the invention relates to a novel class of polypeptides which may have interleukin or cytokine activity.
